The EU Antiplatelet and Antithrombotics Drug market reached a value of nearly $XX million in 2022 and the market is expected to grow to $XX million in 2030 with a CAGR of XX %
Antiplatelet drugs, often called as platelet agglutination inhibitors are a class of therapeutics that help in reducing or preventing the blood coagulation by limiting the activity of platelets to stick or bind together. Clotting of blood is physiological action of the body which helps in controlling external bleeding during the time of injuries. Hence antiplatelet drug agents are therapeutically used to stop clotting as soon as possible. However, limitations in efficacy, safety, and tolerability of some antiplatelet drugs have precluded their use in patients. For instance, antiplatelet drugs can irritate the lining of the stomach that leads to gastrointestinal side effects such as indigestion and stomach aches. Moreover, patients using these drugs can be more prone to nosebleeds, bruising, or bleeding for longer than usual since they reduce the ability of the blood to clot. These factors are expected to hinder the growth of the antiplatelet drug market during the forecast period.
Market Growth Drivers
The increasing cases of cardiac and cancer diseases in the EU is one of the factors which is expected to drive the overall anti-platelet and anti-thrombotic drug market. The significant growth in a market over a forecast period is mainly attributed to hereditary diseases. The unavailability of alternatives for antithrombotic drugs coupled with the new product developments and launches are expected to bolster the market growth. Changing lifestyles and lack of physical activity is one of the factors which affects the growth of the market moderately during the forecast period. Failure to take antiplatelet drugs as prescribed can possess an increased risk of thrombotic complications, owing to rebound platelet activation. All these factors are expected to hinder the growth of the antiplatelet drug market during the forecast period.